Pharmafile Logo
Pharmafocus logo
Advanced Search

cardiovascular

Showing 15 posts of 42 posts found.

astrazeneca_building_white

AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study

November 12, 2018
Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …

News
staphylococcus_aureus_50000x_usda_ars_emu

Researchers design new class of drugs to counter cardiovascular disease

August 14, 2018
Manufacturing and Production TMAO, cardiovascular, gut microbe, heart attack, research

Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by …

News
pharmafile_srping_2018_cover

The new and improved Spring 2018 edition of Pharmafile is available to read online now!

May 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile

The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …

News
heart_rope

Google develops AI to predict cardiovascular risk

February 21, 2018
Research and Development AI, Verily Life Sciences, biotech, cardiovascular, drugs, google, pharma, pharmaceutical

Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …

News
novartis_side_building

Novartis targets specific patient population with strong Ilaris Phase 3 data

November 14, 2017
Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …

News
astrazeneca-sign

AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

September 7, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …

News
astrazeneca_building_white

Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk

August 24, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical

New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …

News
heart_patch

Mending broken hearts with an injectable patch

August 16, 2017
Research and Development biotech, cardiovascular, drugs, heart disease, pharma, pharmaceutical

A team of researchers from the University of Toronto have confronted a problem that had previously had no solution – …

News
heart-2372134_640

Heart failure mortality rates fall across England and Wales, national audit finds

August 11, 2017
Medical Communications, Research and Development cardiovascular, heart, heart disease, life sciences, pharma, pharmaceutical

Great news in the cardiovascular space as results from the National Heart Failure Audit indicate that better treatment has led …

News
blood-1813410_960_720

Heart scan offers possibility of non-invasive diagnosis

July 13, 2017
Medical Communications, Research and Development biotech, cardiovascular, drugs, heart, heart scan, pharma, pharmaceutical

Scientists from the University of Oxford have developed a heart scan that can identify inflammation around arteries that can suggest …

News
novartis_window

Novartis and Ionis enter $1bn cardiovascular drug deal

January 6, 2017
Medical Communications, Research and Development, Sales and Marketing Akcea, Akcea Therapeutics, Ionis, Ionis Pharmaceuticals, cardiovascular

Ionis Pharmaceuticals and one of its wholly-owned subsidiaries Akcea Therapeutics have entered into a partnership with Novartis worth potentially more …

News

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …

News
eli_lilly_logo

Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication

June 30, 2016
Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance

US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …

News
hold_heart

Chiesi set to acquire Medicine Co cardiovascular assets, say reports

May 9, 2016
Sales and Marketing Chiesi, assets, cardiovascular, medicine co

Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …

News
novartis_window

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016
Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024